Solving the Mystery of Myelodysplasia

1. HeaneyMLGoldeDW

1999

Myelodysplasia.

New Engl J Med

340

1649

1660

2. BennettJMCatovskyDDanielMTFlandrinGGaltonDA

1982

Proposals for the classification of the myelodysplastic syndromes.

Br J Haematol

51

189

199

3. VardimanJWHarrisNLBrunningRD

2002

The World Health Organization (WHO) classification of the myeloid neoplasms.

Blood

100

2292

2302

4. GreenbergPCoxCLeBeauMMFenauxPMorelP

1997

International scoring system for evaluating prognosis in myelodysplastic syndromes.

Blood

89

2079

2088

5. Pedersen-BjergaardJAndersenMTAndersenMK

2007

Genetic pathways in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia.

Hematology Am Soc Hematol Educ Program

2007

392

397

6. FenauxPMorelPLaiJL

1996

Cytogenetics of myelodysplastic syndromes.

Semin Hematol

33

127

138

7. LeeYTMillerLDGubinANMakhloufFWojdaU

2001

Transcription patterning of uncoupled proliferation and differentiation in myelodysplastic bone marrow with erythroid-focused arrays.

Blood

98

1914

1921

8. AndersonJEAppelbaumFRFisherLDSchochGShulmanH

1993

Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome.

Blood

82

677

681

9. ScottBDeegHJ

2006

Hemopoietic cell transplantation as curative therapy of myelodysplastic syndromes and myeloproliferative disorders.

Best Pract Res

19

519

533

10. DeegHJStorerBSlatteryJTAnasettiCDoneyKC

2002

Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome.

Blood

100

1201

1207

11. ScottBLSandmaierBMStorerBMarisMBSorrorML

2006

Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis.

Leukemia

20

128

135

12. KantarjianHOkiYGarcia-ManeroGHuangXO'BrienS

2007

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

Blood

109

52

57

13. SilvermanLRDemakosEPPetersonBLKornblithABHollandJC

2002

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

J Clin Oncol

20

2429

2440

14. DeegHJGotlibJBeckhamCDuganKHolmbergL

2002

Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study.

Leukemia

16

162

164

15. DeegHJJiangPYHolmbergLAScottBPetersdorfEW

2004

Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells.

Leuk Res

28

1177

1180

16. ListADewaldGBennettJGiagounidisARazaA

2006

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

New Engl J Med

355

1456

1465

17. ListAKurtinSRoeDJBureshAMahadevanD

2005

Efficacy of lenalidomide in myelodysplastic syndromes.

New Engl J Med

352

549

557

18. EbertBLGaliliNTamayoPBoscoJMakR

2008

An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome.

PLoS Med

5

1

e35

doi:10.1371/journal.pmed.0050035